All Title Author
Keywords Abstract

Usefulness of Fractional Exhaled Nitric Oxide-Guided Treatment in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap

DOI: 10.4236/ojrd.2018.81001, PP. 1-12

Keywords: Asthma-COPD Overlap, Budesonide/Formoterol Combination, COPD Assessment Test, Fractional Exhaled Nitric Oxide

Full-Text   Cite this paper   Add to My Lib


Background: Some patients present clinical features of both asthma and chronic obstructive pulmonary disease (COPD), which has led to the recent proposal of asthma-COPD overlap (ACO) as a diagnosis. Fractional exhaled nitric oxide (FeNO) is a candidate biomarker to diagnose ACO. We assessed the effect of an add-on treatment with budesonide/formoterol (BUD/FM) combination in patients with ACO, which was diagnosed by FeNO. Methods: This was a prospective, single-arm, open-label, before and after comparison study. Subjects included 83 patients with COPD who attended outpatient clinics for routine checkups at Shizuoka General Hospital between June and November 2016. All patients fulfilled the GOLD definition of COPD and were receiving long-acting muscarinic antagonist (LAMA) or LAMA/long-acting β2 agonist (LABA) combinations. After an 8-week run-in period, BUD/FM was added to the patients with FeNO levels of ≥35 ppb, defined as having ACO. For patients receiving LAMA/LABA, BUD/FM was added after the discontinuation of LABA. The modified British Medical Research Council (mMRC) score, COPD assessment test (CAT) score, spirometric indices, forced oscillation parameters, and FeNO were assessed before and after 8 weeks of BUD/ FM add-on treatment. Results: Twenty-four patients (28.9%) had FeNO levels ≥ 35 ppb, and 17 patients completed the study (mean age: 73 years and GOLD I/II/III/IV, 5/10/1/1). The mean CAT scores significantly improved (9.2 to 5.4, p = 0.015) and 10 patients (58.8%) showed ≥2 points improvement, a minimal clinically important difference. The mean FeNO levels significantly decreased from 63.0 to 34.3 ppb (p < 0.006). However, there were no changes in mMRC scores, spirometric indices, or forced oscillation parameters. Conclusions: FeNO-guided treatment with BUD/FM improves symptoms in patients with ACO.


[1]  Global Initiative for Asthma (2017) Global Strategy for Asthma Management and Prevention.
[2]  Barnes, P.J. (2016) Asthma-COPD Overlap. Chest, 149, 7-8.
[3]  Woodruff, P.G., van den Berge, M., Boucher, R.C., Brightling, C., Burchard, E.G., Christenson, S.A., et al. (2017) American Thoracic Soxiety/National Heart, Lung, and Blood Institute Asthma-Chronic Obstructive Pulmonary Disease Overlap Workshop Report. American Journal of Respiratory and Critical Care Medicine, 196, 375-381.
[4]  George, L. and Brightling, C.E. (2016) Eosinophilic Airway Inflammation: Role in Asthma and Chronic Obstructive Pulmonary Disease. Therapeutic Advances in Chronic Disease, 7, 34-51.
[5]  Hinds, D.R., Di Santostefano, R.L., Le, H.V. and Pascoe, S. (2016) Identification of Responders to Inhaled Corticosteroids in a Chronic Obstructive Pulmonary Disease Population Using Cluster Analysis. BMJ Open, 6, e010099.
[6]  Pavord, I.D., Lettis, S., Locantore, N., Pascoe, S., Jones, P.W., Wedzicha, J.A., et al. (2016) Blood Eosinophils and Inhaled Corticosteroid/Long-Acting Beta-2 Agonist Efficacy in COPD. Thorax, 71, 118-125.
[7]  Vedel-Krogh, S., Nielsen, S.F., Lange, P., Vestbo, J. and Nordestgaard, B.G. (2016) Blood Eosinophils and Exacerbations in Chronic Obstructive Pulmonary Disease. The Copenhagen General Population Study. American Journal of Respiratory and Critical Care Medicine, 193, 965-974.
[8]  Siddiqui, S.H., Guasconi, A., Vestbo, J., Jones, P., Agusti, A., Paggiaro, P., et al. (2015) Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 192, 523-525.
[9]  Pascoe, S., Locantore, N., Dransfield, M.T., Barnes, N.C. and Pavord, I.D. (2015) Blood Eosinophil Counts, Exacerbations, and Response to the Addition of Inhaled Fluticasone Furoate to Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of Data from Two Parallel Randomised Controlled Trials. Lancet Respiratory Medicine, 3, 435-442.
[10]  Barnes, N.C., Sharma, R., Lettis, S. and Calverley, P.M. (2016) Blood Eosinophils as a Marker of Response to Inhaled Corticosteroids in COPD. European Respiratory Journal, 47, 1374-1382.
[11]  Donohue, J.F., Herje, N., Crater, G. and Rickard, K. (2014) Characterization of Airway Inflammation in Patients with COPD using Fractional Exhaled Nitric Oxide Levels: A Pilot Study. International Journal of Chronic Obstructive Pulmonary Disease, 16, 745-751.
[12]  Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.
[13]  Bestall, J.C., Paul, E.A., Garrod, R., Garnham, R., Jones, P.W. and Wedzicha, J.A. (1999) Usefulness of the Medical Research Council (MRC) Dyspnea Scale as a Measure of Disability in Patients with Chronic Obstructive Pulmonary Disease. Thorax, 54, 581-586.
[14]  Jones, P.W., Harding, G., Berry, P., Wiklund, I., Chen, W.-H. and Leidy, N.K. (2009) Development and First Validation of the COPD Assessment Test. European Respiratory Journal, 34, 648-654.
[15]  American Thoracic Society, European Respiratory Society (2005) ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. American Journal of Respiratory and Critical Care Medicine, 171, 912-930.
[16]  Dweik, R.A., Sorkness, R.L., Wenzel, S., Hammel, J., Curran-Everett, D., Comhair, S.A.A., et al. (2010) Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, At-Risk Phenotype among Patients with Asthma. American Journal of Respiratory and Critical Care Medicine, 181, 1033-1041.
[17]  Oostveen, E., Macleod, D., Lorino, H., Farre, R., Hantos, Z., Desager, K., et al. (2003) The Forced Oscillation Technique in Clinical Practice: Methodology, Recommendations and Future Developments. European Respiratory Journal, 22, 1026-1041.
[18]  Miller, M.R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., et al. (2005) Standardisation of Spirometry. European Respiratory Journal, 26, 319-338.
[19]  The Committee of Pulmonary Physiology, Japanese Respiratory Society (2004) Guidelines for Pulmonary Function Tests. Spirometry, Flow-Volume Curve, Diffusing Capacity of the Lung. Japanese Respiratory Society, Tokyo.
[20]  Kanda, Y. (2013) Investigation of the Freely Available Easy-to-Use Software “EZR” for Medical Statistics. Bone Marrow Transplantation, 48, 452-458.
[21]  Katial, R.K., Bensch, G.W., Busse, W.W., Chipps, B.E., Denson, J.L., Gerber, A.N., et al. (2017) Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. Journal of Allergy and Clinical Immunology: In Practice, 5, S1-S14.
[22]  Tamada, T., Sugiura, H., Takahashi, T., Matsunaga, K., Kimura, K., Katsumata, U., et al. (2015) Biomarker-Based Detection of Asthma-COPD Overlap Syndrome in COPD Populations. International Journal of Chronic Obstructive Pulmonary Disease, 10, 2169-2176.
[23]  Szafranski, W., Cukier, A., Ramirez, A., Menga, G., Sansores, R., Nahabedian, S., et al. (2003) Efficacy and Safety of Budesonide/Formoterol in the Management of Chronic Obstructive Pulmonary Disease. European Respiratory Journal, 21, 74-81.
[24]  Welte, T., Miravitlles, M., Hernandez, P., Eriksson, G., Peterson, S., Polanowski, T., et al. (2009) Efficacy and Tolerability of Budesonide/Formoterol Added to Tiotropium in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 180, 741-750.
[25]  Kondo, M. and Tamaoki, J. (2017) Therapeutic Approaches of Asthma and COPD Overlap. Allergology International.


comments powered by Disqus